Annual report pursuant to Section 13 and 15(d)

Subsequent Events - AnnJi License Agreement (Details)

v3.23.1
Subsequent Events - AnnJi License Agreement (Details) - Subsequent events - AnnJi License Agreement
$ in Millions
Feb. 28, 2023
USD ($)
shares
Subsequent Events  
Initial cash license fee $ 3.0
Maximum reimbursement payments in connection with the clinical trial 10.8
Maximum amount payable in connection with development milestones of first indication in the U.S 14.5
Maximum payables with milestones pertaining to additional indications and development outside the U.S 27.5
Maximum amount upon the achievement of certain net sales milestones 165.0
Maximum annual net sales for royalty payments 300.0
Minimum annual net sales for royalty payments $ 50.0
Issue of shares in connection with the signing of the License Agreement | shares 831,618
Issue of additional shares of common stock upon enrollment of the eighth patient | shares 276,652
Minimum  
Subsequent Events  
Threshold period for license fee 60 days
Annual net sales for milestone payment $ 75.0
Maximum  
Subsequent Events  
Threshold period for license fee 180 days
Annual net sales for milestone payment $ 750.0
License fee payable within 60 days  
Subsequent Events  
Initial cash license fee 2.0
License fee payable within 180 days  
Subsequent Events  
Initial cash license fee $ 1.0